Shiba K, Yoshida M, Shimada J, Saito A, Matsubayashi K, Hashimoto S, Yoshida K, Osada Y, Sakai O
Second Department of Internal Medicine, Jikei University, School of Medicine, Tokyo, Japan.
Chemotherapy. 1992;38(6):369-75. doi: 10.1159/000239029.
A total of 5 healthy volunteers were enrolled in a crossover study on the dose dependency and the effect of probenecid on pharmacokinetics of DQ-2556. They were administered intravenously 0.5 and 1.0 g of DQ-2556, and 1.0 g of DQ-2556 with oral administration of probenecid. The linearity in pharmacokinetics of DQ-2556 was confirmed up to the dose of 1.0 g. In the case of 1.0 g of DQ-2556 with probenecid treatment, the area under the serum concentration-time curve was larger, and total and renal clearances were less than those in the case of 1.0 g of DQ-2556 alone (by approximately 15% for each parameter, p < 0.01). These results demonstrated that DQ-2556 is secreted in the renal tubule, although it is excreted mainly by the glomerular filtration.
共有5名健康志愿者参与了一项关于丙磺舒对DQ - 2556药代动力学的剂量依赖性及影响的交叉研究。他们静脉注射了0.5克和1.0克的DQ - 2556,以及1.0克的DQ - 2556并口服丙磺舒。在剂量达到1.0克时,证实了DQ - 2556药代动力学的线性关系。在1.0克DQ - 2556联合丙磺舒治疗的情况下,血清浓度 - 时间曲线下面积更大,总清除率和肾清除率低于单独使用1.0克DQ - 2556的情况(每个参数约低15%,p < 0.01)。这些结果表明,尽管DQ - 2556主要通过肾小球滤过排泄,但它也在肾小管中分泌。